LINC01495: A Potential Drug Target and Biomarker (G102723378)

Target Name: LINC01495

NCBI ID: G102723378

LINC01495

Other Name(s): Long intergenic non-protein coding RNA 1495 | long intergenic non-protein coding RNA 1495

LINC01495: A Potential Drug Target and Biomarker

LINC01495 is a non-protein coding RNA (ncRNA) molecule located in chromosome 6p21.1. It has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery of LINC01495

LINC01495 was first identified in a large-scale RNA sequencing (RNA-seq) study using the R package. The RNA-seq data revealed that LINC01495 was expressed in various tissues and cells, including brain, heart, liver, and pancreas, and at different stages of development.

The functions of LINC01495

LINC01495 is involved in the regulation of gene expression and has been shown to play a role in various biological processes, including cell growth, apoptosis, and inflammation.

Additionally, LINC01495 has been associated with several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, LINC01495 has been shown to be overexpressed in various cancer types, and it has been used as a biomarker for cancer diagnosis and treatment.

The potential implications of LINC01495 as a drug target

The potential implications of LINC01495 as a drug target are significant. If LINC01495 is indeed involved in the development and progression of various diseases, targeting it with drugs could be an effective way to treat these conditions.

For example, LINC01495 has been shown to play a role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. By targeting LINC01495 with drugs, researchers could potentially develop new treatments for these debilitating diseases.

LINC01495 may also be a useful biomarker for tracking the effectiveness of drugs in these diseases. By measuring the levels of LINC01495 in brain or other affected tissues, researchers could determine whether the drug is effectively treating the disease and whether it is having the desired impact on patient outcomes.

The potential implications of LINC01495 as a cancer biomarker

LINC01495 has also been shown to be overexpressed in various types of cancer, making it an attractive candidate as a cancer biomarker. By measuring the levels of LINC01495 in cancer cells or tissue samples, researchers could potentially develop new diagnostic tests or biomarkers for cancer.

Additionally, LINC01495 has been shown to play a role in the development and progression of certain types of cancer, such as breast cancer and colon cancer. By targeting LINC01495 with drugs, researchers could potentially develop new treatments for these cancers.

The potential implications of LINC01495 as a drug target

The potential implications of LINC01495 as a drug target are significant. If LINC01495 is involved in the development and progression of various diseases, targeting it with drugs could be an effective way to treat these conditions.

For example, LINC01495 has been shown to play a role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. By targeting LINC01495 with drugs, researchers could potentially develop new treatments for these debilitating diseases.

LINC01495 may also be

Protein Name: Long Intergenic Non-protein Coding RNA 1495

The "LINC01495 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01495 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets